Kissei Pharmaceutical Co., Ltd. (4547.T) JPX

4,155.00

+10(+0.24%)

Updated at October 20 10:30AM

Currency In JPY

Kissei Pharmaceutical Co., Ltd.

Address

19-48, Yoshino

Matsumoto, 399-8710

Japan

Phone

81 263 25 9081

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

1779

First IPO Date

January 01, 2001

Key Executives

NameTitlePayYear Born
Mr. Mutsuo KanzawaChairman & Chief Executive Officer01949
Mr. Tetsu TakayamaExecutive MD & Director01961
Hiroshi NoakeGM of Pharmaceutical Sales Headquarters & Director01964
Keiji MiyazawaGM of Research Division & Director01967
Mr. Yasuo TakehanaPresident, Chief Operating Officer & Director01960
Mr. Takahide KitaharaGM of Financial Management Department, MD & Director01962
Mr. Yoshio FurihataSenior Advisor & Director01962
Mr. Keiji FukushimaExecutive Vice President & Director01956

Description

Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. The company's products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. It is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was founded in 1946 and is headquartered in Matsumoto, Japan.